239 related articles for article (PubMed ID: 12678747)
21. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
22. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationship in Ftorafur (Tegafur) and related 5-FU prodrugs.
Zhuk R
Adv Exp Med Biol; 1998; 431():677-80. PubMed ID: 9598151
[No Abstract] [Full Text] [Related]
24. Drug delivery of oral anti-cancer fluoropyrimidine agents.
Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
[TBL] [Abstract][Full Text] [Related]
25. Uridine phosphorylase (-/-) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines.
Cao D; Russell RL; Zhang D; Leffert JJ; Pizzorno G
Cancer Res; 2002 Apr; 62(8):2313-7. PubMed ID: 11956089
[TBL] [Abstract][Full Text] [Related]
26. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer.
Wagstaff AJ; Ibbotson T; Goa KL
Drugs; 2003; 63(2):217-36. PubMed ID: 12515569
[TBL] [Abstract][Full Text] [Related]
27. Practical considerations in the use of oral fluoropyrimidines.
Hoff PM
Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799
[TBL] [Abstract][Full Text] [Related]
28. Safety of capecitabine: a review.
Mikhail SE; Sun JF; Marshall JL
Expert Opin Drug Saf; 2010 Sep; 9(5):831-41. PubMed ID: 20722491
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy of colorectal cancer: history and new themes.
Bertino JR
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-3-S18-7. PubMed ID: 9420015
[TBL] [Abstract][Full Text] [Related]
30. The oral fluoropyrimidines in cancer chemotherapy.
Lamont EB; Schilsky RL
Clin Cancer Res; 1999 Sep; 5(9):2289-96. PubMed ID: 10499595
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
32. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer.
Ignoffo RJ
Am J Health Syst Pharm; 1999 Dec; 56(23):2417-28; quiz 2428-9. PubMed ID: 10595802
[TBL] [Abstract][Full Text] [Related]
33. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents.
Tanaka F; Fukuse T; Wada H; Fukushima M
Curr Pharm Biotechnol; 2000 Sep; 1(2):137-64. PubMed ID: 11467334
[TBL] [Abstract][Full Text] [Related]
34. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
Folprecht G; Köhne CH
Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
[TBL] [Abstract][Full Text] [Related]
35. Development of 5-Fluorouracil derivatives as anticancer agents.
Pan X; Wang C; Wang F; Li P; Hu Z; Shan Y; Zhang J
Curr Med Chem; 2011; 18(29):4538-56. PubMed ID: 21864282
[TBL] [Abstract][Full Text] [Related]
36. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
37. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration.
Yang YW; Lee JS; Kim I; Jung YJ; Kim YM
Eur J Pharm Biopharm; 2007 May; 66(2):260-7. PubMed ID: 17182232
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine: a novel agent for the treatment of solid tumors.
Johnston PG; Kaye S
Anticancer Drugs; 2001 Sep; 12(8):639-46. PubMed ID: 11604550
[TBL] [Abstract][Full Text] [Related]
40. Other fluorinated pyrimidines in the treatment of solid tumors.
Saad ED; Hoff PM
Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):65-8. PubMed ID: 11219980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
